Zentalis Pharmaceuticals (ZNTL) Cash from Investing Activities (2019 - 2026)

Zentalis Pharmaceuticals has reported Cash from Investing Activities for 8 years, with the latest figure at $30.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 25.85% year-over-year to $30.0 million; the trailing twelve-month figure through Mar 2026 stood at $121.2 million (down 22.08% YoY), and the FY2025 full-year result was $131.6 million, down 25.45% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $30.0 million, down from $32.4 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $72.9 million in Q2 2023, with the low at -$142.1 million in Q2 2022.
• Average Cash from Investing Activities over 5 years is $10.6 million, with a median of $30.4 million recorded in 2025.
• Year-over-year, Cash from Investing Activities plunged 686.73% in 2023 and soared 176.75% in 2024.
• Tracing ZNTL's Cash from Investing Activities over 5 years: stood at -$11.9 million in 2022, then sank by 253.62% to -$42.1 million in 2023, then surged by 176.75% to $32.3 million in 2024, then climbed by 0.51% to $32.4 million in 2025, then slipped by 7.5% to $30.0 million in 2026.
• The last three Cash from Investing Activities figures came in at $30.0 million (Q1 2026), $32.4 million (Q4 2025), and $28.3 million (Q3 2025), per Business Quant data.

Peer Comparison